Inventiva (NASDAQ:IVA) is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH). The company is listed on both Euronext Paris and Nasdaq. Inventiva is advancing its Phase 3 clinical trial for MASH, a significant step in its mission to provide therapeutic solutions for millions of patients.
On September 25, 2025, Inventiva reported an earnings per share (EPS) of -$0.64, which was below the estimated EPS of -$0.41. Despite this, the company generated a revenue of approximately $5.24 million, slightly surpassing the estimated revenue. This performance reflects the challenges and opportunities faced by Inventiva as it progresses in its clinical programs.
Inventiva's financial position has been bolstered by a €116 million tranche of structured financing, as highlighted by the randomization of the last patient in the NATiV3 study. This financing is crucial as the company prepares for upcoming data readouts and potential regulatory submissions. As of June 30, 2025, Inventiva reported cash and cash equivalents totaling €146.7 million, ensuring a cash runway until the end of the third quarter of 2026.
The company's financial metrics indicate a challenging environment. With a price-to-earnings (P/E) ratio of approximately -1.46, Inventiva is experiencing negative earnings. The price-to-sales ratio of about 33.51 suggests that investors are paying $33.51 for every dollar of sales. Additionally, the enterprise value to sales ratio is approximately 28.92, reflecting the company's valuation relative to its sales.
Inventiva's debt-to-equity ratio is about -0.51, indicating more liabilities than equity. The current ratio of approximately 0.92 suggests potential difficulty in covering short-term liabilities with short-term assets. Despite these challenges, the company remains focused on its clinical advancements and financial strategies to support its long-term goals.
